live better, longer
Testosterone replacement therapy can improve bone mineral density and bone strength in some men with clinically confirmed low testosterone. However, increased bone density does not necessarily mean fewer fractures.
Research shows that testosterone plays an important role in maintaining healthy bones, supporting muscle mass, and regulating bone remodeling.
Men with low testosterone may also have low estradiol, a hormone that is essential for maintaining bone density in both men and women.
When testosterone deficiency is appropriately diagnosed and treated, bone density may improve.
However, a large clinical trial published in the New England Journal of Medicine in 2024 found that testosterone treatment did not reduce clinical fractures in middle-aged and older men with hypogonadism. In fact, fractures occurred more frequently in the testosterone group.
This distinction is important.
Testosterone may be an appropriate treatment for certain men with hypogonadism, but it should not automatically replace established osteoporosis medications in men at high fracture risk.
Let's look at how testosterone affects bone health, what the research tells us, and when hormone treatment may be worth discussing.
Yes. Osteoporosis affects both men and women.
Although women are more frequently diagnosed, men can experience significant bone loss and fragility fractures.
Osteoporosis occurs when bone strength declines enough to increase the likelihood of fractures.
For men, the condition can be particularly easy to overlook.
Many men assume osteoporosis is a women's health issue.
Others may not receive bone density screening until they experience a fracture.
But osteoporosis in men deserves serious attention, especially because hip and vertebral fractures can lead to substantial disability and loss of independence.
Several factors may contribute to bone loss in men.
These include:
In many cases, more than one factor is involved.
That is why evaluating osteoporosis in men should go beyond a single DEXA scan.
Testosterone is one of the primary sex hormones in men.
It influences muscle mass, strength, body composition, sexual function, and several metabolic processes.
It also plays an important role in bone development and maintenance.
During puberty, testosterone helps men develop greater skeletal size and strength.
Throughout adulthood, adequate sex hormone activity helps regulate bone remodeling.
Testosterone influences bone health through two important pathways.
Testosterone acts through androgen receptors found in bone-related tissues.
Androgen signaling contributes to skeletal development and maintenance.
It also influences muscle mass, which matters because stronger muscles place mechanical forces on bones during movement and resistance training.
Those forces help stimulate the skeleton.
An important and often overlooked point is that men need estradiol for healthy bones.
Estradiol is commonly described as a female hormone, but it has an essential role in male physiology as well.
Men produce much of their estradiol through a process called aromatization, in which the enzyme aromatase converts testosterone into estradiol.
Estradiol helps regulate bone resorption.
Without adequate estradiol activity, bone breakdown can accelerate.
This means that a man with low testosterone may experience bone-related consequences partly because his estradiol is also insufficient.
Yes. Testosterone deficiency is a recognized contributor to low bone density and osteoporosis in men.
When testosterone levels decline, several changes may occur.
Muscle mass may decrease, strength can decline, and the hormonal environment supporting bone maintenance may become less favorable.
If estradiol also declines, bone resorption may increase.
Over time, these changes can contribute to lower bone mineral density and higher fracture risk.
But not every man with osteoporosis has low testosterone.
And not every man with low testosterone develops osteoporosis.
This is why hormone testing needs to be considered alongside a comprehensive bone health evaluation.
Symptoms of testosterone deficiency may include reduced sexual desire, erectile dysfunction, decreased spontaneous erections, fatigue, reduced muscle mass, or other changes in physical function.
However, many of these symptoms are nonspecific.
Fatigue, for example, can also result from poor sleep, thyroid dysfunction, depression, anemia, medication effects, or chronic illness.
A diagnosis of hypogonadism requires more than symptoms alone.
It generally involves compatible clinical findings together with consistently low testosterone levels confirmed by appropriate laboratory testing.
Your provider may also evaluate free testosterone, luteinizing hormone, and other markers to determine whether a deficiency is present and what may be causing it.
Research has shown that testosterone replacement can improve certain measures of bone density and bone structure in men with low testosterone.
These changes are particularly interesting because testosterone may support both hormonal signaling and muscle-related skeletal loading.
Some clinical trials have reported improvements in spine bone density and measures of bone strength after testosterone treatment.
But results vary.
The amount of improvement depends on factors such as baseline hormone levels, age, treatment duration, existing bone health, and other medical conditions.
The spine and hip may also respond differently.
This matters because different skeletal sites contain different proportions of trabecular and cortical bone.
The spine contains more trabecular bone, which tends to remodel relatively quickly.
The hip contains substantial cortical bone, which may respond more slowly.
Therefore, an improvement in spine bone density does not necessarily mean an equivalent improvement at the hip.
This is where we need to distinguish between two different outcomes.
Bone mineral density is a measurement. Fracture prevention is a clinical outcome.
A medication can improve bone mineral density without necessarily proving that it prevents fractures.
For years, researchers observed improvements in bone density and strength with testosterone replacement.
That led to the reasonable hypothesis that testosterone might reduce fracture risk.
However, direct fracture-outcome research has complicated that assumption.
A large randomized clinical trial published in the New England Journal of Medicine evaluated fractures among men receiving testosterone treatment.
The study included 5,204 middle-aged and older men with hypogonadism.
Participants received testosterone gel or placebo.
After a median follow-up of approximately 3.2 years, clinical fractures occurred in:
The researchers found that testosterone treatment did not reduce clinical fractures.
Fractures were more frequent in the testosterone group, although the study did not establish exactly why that occurred.
This is important because the finding differs from what might have been expected based on previous improvements in bone density.
It means we should not assume that testosterone replacement alone prevents fragility fractures.
Testosterone may still be appropriate for men with clinically diagnosed hypogonadism.
But improving testosterone levels and treating osteoporosis are not necessarily the same thing.
For men at high fracture risk, an osteoporosis medication with demonstrated antifracture efficacy may still be needed.
A comprehensive approach should evaluate both conditions rather than assuming one intervention solves everything.
Testosterone replacement may improve bone mineral density in some men with hypogonadism.
However, it is not possible to guarantee that testosterone will reverse osteoporosis.
Bone loss usually has multiple causes.
Even when testosterone deficiency is present, additional factors may limit the response.
These may include inadequate mechanical loading, insufficient nutrition, chronic inflammation, age-related changes, medications, or other medical conditions.
Some men may experience meaningful improvements in bone density after their hormone deficiency is treated.
Others may see smaller changes.
And some will continue to need osteoporosis-specific medication.
The goal should not be to promise reversal from a single intervention.
The goal should be to identify the factors contributing to bone loss and develop a plan that meaningfully reduces fracture risk.
Dr. Doug Lucas describes a 64-year-old patient who entered a comprehensive bone health program after receiving an osteoporosis diagnosis.
The patient was a retired attorney who had recently experienced substantial changes in his daily routine.
He was also an avid cyclist.
Although cycling provided cardiovascular exercise, he was not regularly performing the type of progressive resistance training that could meaningfully challenge his bones.
The initial intervention focused on nutrition, exercise, sleep, and stress.
During the first year, the patient experienced improvement, but progress was relatively slow.
After further hormone evaluation, testosterone replacement was introduced.
Dr. Doug observed that the patient's bone density improved more rapidly after testosterone was added.
This case illustrates why evaluating hormone status can matter.
However, it is important to recognize that this is a clinical observation involving one patient.
It cannot establish that testosterone caused the improvement or that similar results should be expected in every man with osteoporosis.
The value of the example is the broader lesson: when bone health progress is limited, it may be worth investigating additional contributing factors rather than assuming the existing plan is complete.
Estradiol deserves much more attention in discussions about male bone health.
Although men generally have lower estradiol levels than premenopausal women, the hormone is essential for maintaining skeletal integrity.
Estradiol influences osteoclast activity and helps prevent excessive bone resorption.
Men with insufficient estradiol activity may be more vulnerable to bone loss.
This is one reason low testosterone can have consequences beyond the direct loss of androgen signaling.
When testosterone declines, the amount available for conversion into estradiol may also decline.
However, estradiol levels do not always track perfectly with testosterone.
Body composition, aromatase activity, medications, and individual physiology can influence the relationship.
Therefore, hormone evaluation should be individualized.
Aromatase inhibitors reduce the conversion of testosterone into estradiol.
These medications are sometimes used in men for specific medical reasons.
But suppressing estradiol too aggressively may negatively affect bone health.
For men with osteoporosis or low bone density, this deserves particular attention.
It is important not to assume that lower estradiol is always better for men.
Both testosterone and estradiol play valuable physiological roles.
Testing may be appropriate, particularly when osteoporosis is accompanied by symptoms of hypogonadism or other findings suggesting hormone deficiency.
A clinician may consider evaluating:
Additional testing may be necessary to investigate secondary causes of osteoporosis.
Not every man needs every test.
The goal is to determine whether hormone dysfunction or another underlying condition is contributing to skeletal decline.
Testosterone replacement has potential benefits and risks.
It should only be prescribed when there is a legitimate medical indication and after appropriate assessment.
Potential concerns include increased hematocrit, acne, changes in fertility, sleep apnea considerations, prostate-related monitoring, and other treatment-specific risks.
Testosterone therapy also requires careful consideration of cardiovascular history and overall health.
These risks do not automatically mean treatment should be avoided.
They mean it should be used appropriately and monitored.
For men with clinically confirmed hypogonadism, treating testosterone deficiency may improve symptoms and certain aspects of physical function.
But the decision should not be based solely on a desire to raise bone density.
These treatments serve different purposes.
Testosterone replacement is intended to treat clinically diagnosed testosterone deficiency.
Osteoporosis medications are intended to improve skeletal outcomes and reduce fracture risk in appropriate patients.
Some men may need one.
Some may need both.
And others may benefit primarily from lifestyle changes and treatment of secondary causes.
For men with high fracture risk, clinical guidance generally supports using medications with proven antifracture efficacy rather than relying on testosterone alone.
The decision depends on fracture history, bone mineral density, hormone levels, age, contraindications, and personal goals.
Even when testosterone deficiency is treated, exercise remains essential.
One of the biggest challenges we see in men is the assumption that cardiovascular fitness automatically means strong bones.
It does not.
Cycling, swimming, and walking can be excellent activities.
But they do not necessarily provide the mechanical stimulus needed to meaningfully improve bone density.
For many men, a bone-focused exercise program should include appropriately progressed resistance training and impact or simulated impact when safe.
Resistance training also supports muscle mass, balance, strength, and independence.
These benefits matter even when changes in bone density are modest.
Nutrition provides the foundation for skeletal maintenance.
Men need adequate protein, sufficient calories, and the vitamins and minerals involved in bone metabolism.
Calcium and vitamin D are particularly important when intake or status is inadequate.
Protein supports muscle maintenance and the collagen-rich matrix of bone.
Under-fueling can undermine both muscle and skeletal health.
A complete plan should also consider digestive health, alcohol intake, smoking, and other lifestyle factors.
No single supplement or food can replace the need for adequate nutrition and appropriate mechanical loading.
Monitoring should focus on meaningful changes over time.
A comprehensive assessment may include DEXA imaging, fracture history, fall risk, muscle strength, and laboratory evaluation.
Bone turnover markers such as CTX and P1NP may provide additional information in certain clinical circumstances.
However, no single biomarker can reliably establish that a person is building stronger bones or experiencing a lower fracture risk.
Imaging changes slowly, and hormone levels do not tell the entire story.
This is why clinical follow-up should evaluate the overall treatment response rather than focusing exclusively on testosterone or a T-score.
Testosterone replacement can improve bone mineral density in some men with clinically diagnosed low testosterone. The degree of improvement varies, and increased density does not guarantee fewer fractures.
Yes. Low testosterone can contribute to bone loss directly and through reduced estradiol activity. However, osteoporosis in men can have many causes.
A large randomized trial published in 2024 did not find fewer clinical fractures with testosterone treatment. Fractures were more frequent in the testosterone group than in the placebo group.
Not automatically. Men at high fracture risk may need osteoporosis medications with established fracture-prevention benefits, even if they also receive testosterone replacement.
Estradiol testing may be useful in selected men, particularly when hormone deficiency, aromatase inhibitor use, or other endocrine issues are suspected.
Cycling supports cardiovascular health but does not provide the same weight-bearing and impact stimulus as resistance or impact training. Men who cycle regularly may still need a dedicated bone-strengthening program.
Screening decisions depend on age and risk factors. Men aged 70 and older, and younger men with significant risk factors, should discuss bone density testing with their healthcare provider.
Some men may improve bone density through targeted lifestyle interventions and treatment of underlying causes. However, results vary, and men at high fracture risk may require medication to reduce fracture risk.
Testosterone plays an important role in male bone health.
It supports muscle mass, influences skeletal remodeling, and provides a source for estradiol production.
Men with clinically confirmed low testosterone may experience improvements in bone density when their deficiency is treated.
But testosterone is not a guaranteed osteoporosis treatment.
The latest fracture-outcome research shows why we cannot assume that better bone density automatically means fewer fractures.
The strongest approach is to evaluate the entire clinical picture.
That includes hormones, nutrition, exercise, medications, imaging, fracture history, and other potential contributors to bone loss.
For men with osteoporosis, the goal is not simply to optimize testosterone.
The goal is stronger bones, fewer fractures, and the ability to stay active and independent as they age.
If you've been diagnosed with osteoporosis or low bone density, understanding the cause is one of the most important steps you can take.
Inside The OsteoCollective, we help members learn about the many factors that influence bone health, including hormones, exercise, nutrition, imaging, and treatment options.
Our free Bone Health Masterclass is another place to start.
You'll learn about common mistakes people make when addressing osteoporosis and how to think more clearly about the tools available to support long-term skeletal health.
Because osteoporosis isn't the end. Deciding to take action is the beginning.
This article is for educational purposes only and does not constitute medical advice. Testosterone replacement therapy and osteoporosis treatments require individualized evaluation and medical supervision. Do not begin, discontinue, or adjust testosterone or osteoporosis medication without consulting a qualified healthcare professional. Treatment decisions should account for symptoms, laboratory results, fracture risk, cardiovascular health, fertility considerations, and other relevant medical conditions.
Your Blueprint for Lasting Bone Health and Longevity
.svg)
.svg)
.svg)
.svg)
Join us LIVE November 5th, 2026 at 3:00pm EST to Learn Dr. Doug's proven framework for Osteoporosis Reversal for FREE. Yes! Reversing Osteoporosis is possible and has happened for hundreds of Dr. Doug's patients.
If you have been blind-sided, feel stuck, confused, and exhausted with your diagnosis, this Masterclass is for you!
.svg)
.svg)
